CN101605538A - 瓜氨酸用于治疗营养缺乏状况的用途 - Google Patents

瓜氨酸用于治疗营养缺乏状况的用途 Download PDF

Info

Publication number
CN101605538A
CN101605538A CNA2007800424825A CN200780042482A CN101605538A CN 101605538 A CN101605538 A CN 101605538A CN A2007800424825 A CNA2007800424825 A CN A2007800424825A CN 200780042482 A CN200780042482 A CN 200780042482A CN 101605538 A CN101605538 A CN 101605538A
Authority
CN
China
Prior art keywords
citrulline
protein synthesis
treatment
nutritional
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800424825A
Other languages
English (en)
Chinese (zh)
Inventor
C·莫纳德
M·乔丹
S·沃尔兰德
L·塞诺伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Descartes
Biocodex SAS
Original Assignee
Universite Paris Descartes
Biocodex SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Descartes, Biocodex SAS filed Critical Universite Paris Descartes
Publication of CN101605538A publication Critical patent/CN101605538A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800424825A 2006-10-17 2007-08-29 瓜氨酸用于治疗营养缺乏状况的用途 Pending CN101605538A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR06/09077 2006-10-17
FR0609077A FR2907011B1 (fr) 2006-10-17 2006-10-17 Utilisation de la citrulline pour le traitement des etats de denutrition

Publications (1)

Publication Number Publication Date
CN101605538A true CN101605538A (zh) 2009-12-16

Family

ID=37888135

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800424825A Pending CN101605538A (zh) 2006-10-17 2007-08-29 瓜氨酸用于治疗营养缺乏状况的用途

Country Status (8)

Country Link
US (1) US20100298437A1 (https=)
EP (1) EP2081564B1 (https=)
JP (1) JP2010506887A (https=)
CN (1) CN101605538A (https=)
CA (1) CA2666538A1 (https=)
FR (1) FR2907011B1 (https=)
IL (1) IL198182A0 (https=)
WO (1) WO2008049984A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104263550A (zh) * 2014-09-11 2015-01-07 滁州斯迈特复合材料有限公司 化妆液玻璃瓶清洁剂
CN107921014A (zh) * 2015-09-04 2018-04-17 国立大学法人筑波大学 肌肉增强用组合物和用于增强肌肉的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913885B1 (fr) * 2007-03-22 2012-07-20 Univ Paris Descartes Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
DE102007016715A1 (de) * 2007-04-04 2008-10-09 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren
WO2012005568A1 (en) 2010-07-07 2012-01-12 N.V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
FR2970414B1 (fr) 2011-01-14 2013-03-22 Univ Paris Descartes Action preventive de la citrulline sur le developpement spontane des tumeurs
AU2013392167B2 (en) 2013-06-10 2017-04-27 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
FR3009963B1 (fr) 2013-09-03 2017-03-03 Biolis Composition de lutte contre les troubles de la locomotion
EP2875736B1 (en) 2013-11-26 2016-07-27 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis
JPWO2015137387A1 (ja) * 2014-03-11 2017-04-06 協和発酵バイオ株式会社 筋肉増強剤
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
EP3368498A4 (en) 2015-10-27 2019-06-12 Cytozyme Animal Nutrition, Inc. ANIMAL NUTRITIONAL COMPOSITIONS AND RELATED METHODS
CN112135531A (zh) 2018-03-27 2020-12-25 N·V·努特里奇亚 终生干预期间超重或肥胖成年人的胰岛素控制

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6304M (https=) * 1966-12-15 1968-09-16
FR6306M (https=) * 1966-12-15 1968-09-16
FR6305M (https=) * 1966-12-15 1968-09-16
US5189025A (en) * 1988-12-09 1993-02-23 Board Of Regenets, The University Of Texas System Methods for the treatment of malignant disease in patients using citrulline containing amino acid solutions
US4988724A (en) * 1988-12-09 1991-01-29 Board Of Regents, The University Of Texas System Methods and improved formulations for the determination and treatment of malignant disease in patients
FR2691359B1 (fr) * 1992-05-20 1995-06-23 Krempf Michel Nouvelle application therapeutique du malate de 1-citrulline.
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
FR2857262B1 (fr) * 2003-07-08 2007-10-05 Biocodex Lab Utilisation de la citrulline dans le cadre de l'insuffisance intestinale

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104263550A (zh) * 2014-09-11 2015-01-07 滁州斯迈特复合材料有限公司 化妆液玻璃瓶清洁剂
CN107921014A (zh) * 2015-09-04 2018-04-17 国立大学法人筑波大学 肌肉增强用组合物和用于增强肌肉的方法

Also Published As

Publication number Publication date
US20100298437A1 (en) 2010-11-25
CA2666538A1 (fr) 2008-05-02
EP2081564A2 (fr) 2009-07-29
EP2081564B1 (fr) 2014-01-01
IL198182A0 (en) 2009-12-24
WO2008049984A2 (fr) 2008-05-02
FR2907011A1 (fr) 2008-04-18
FR2907011B1 (fr) 2010-05-14
JP2010506887A (ja) 2010-03-04
WO2008049984A3 (fr) 2008-06-19

Similar Documents

Publication Publication Date Title
CN101605538A (zh) 瓜氨酸用于治疗营养缺乏状况的用途
Grimble Adverse gastrointestinal effects of arginine and related amino acids
Tredget et al. The metabolic effects of thermal injury
TWI777999B (zh) 胺基酸組合物及肝疾病之治療方法
US5576351A (en) Use of arginine as an immunostimulator
Ziegler et al. Efficiency of enteral nitrogen support in surgical patients: small peptides v non-degraded proteins.
Ginguay et al. Indications and contraindications for infusing specific amino acids (leucine, glutamine, arginine, citrulline, and taurine) in critical illness
JP3287842B2 (ja) 免疫刺激剤としてのアルギニンの用途
CN111479580B (zh) 采用自噬诱发剂和高蛋白质的组合来诱发自噬的组合物和方法
ES2924041T3 (es) Materia fecal para la prevención o el tratamiento de enfermedades autoinmunes
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
US20110077198A1 (en) Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition
JP2022538154A (ja) 骨格筋における状態又は障害を予防又は治療するための、トリゴネリン及びビタミンを使用する組成物及び方法
CN101325951A (zh) 富含亮氨酸的组合物
Mullen et al. Role of nutrition in hepatic encephalopathy
PT1427405E (pt) Compostos inibidores de inflamações.
CN101686919A (zh) 瓜氨酸用于治疗与蛋白质羰基化增加相关的病理学状态的用途
US20020002198A1 (en) Chemical synergy to elevate growth hormone release in vertebrates
EP0655244B2 (fr) Composition à base d'acides aminés pour le traitement d'infections
EP1495755B1 (fr) Utilisation de la citrulline dans la fabrication d'un médicament pour le traitement de l'insuffisance intestinale liée au vieillissement ou à une irradiation
CN101090717B (zh) 甘氨酸在制备调节动物体重和体型的组合物中的用途
Farges et al. Oral administration of a glutamine-enriched diet before or after endotoxin challenge in aged rats has limited effects
Ventura et al. Influence of an ω3-fatty acid–enriched enteral diet with and without added glutamine on the metabolic response to injury in a rat model of prolonged acute catabolism
TWI878045B (zh) 雞肉水解物用於治療或預防藥物性肝臟損傷之用途
US20240408044A1 (en) Composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091216